Procarta Biosystems
Procarta Biosystems is a biotechnology company focused on developing innovative antibacterial and antiviral therapies, including snare antibacterials and treatments for infections resistant to traditional antibiotics. They are also engaged in research on microbiome rebalancing and developing solutions for bacterial infections such as MRSA, as well as exploring treatments for viral diseases like COVID-19. Their mission is to create effective, resistance-free therapeutics through proprietary platform technologies, aiming to address the global challenge of antimicrobial resistance and improve human health.
Industries
Nr. of Employees
small (1-50)
Procarta Biosystems
Patents
Products
Oligonucleotide-based nanoparticulate antibacterial platform
A platform technology combining bioinformatics-designed oligonucleotide transcription factor decoys with nanoparticle carriers to inhibit essential bacterial genes and treat infections across designed spectra.
Lead narrow‑spectrum antibacterial candidate (CRE focus)
A lead compound in lead optimisation targeting Carbapenem-resistant Enterobacteriaceae (CRE), intended for development toward first-in-human studies.
Intranasal formulation for decolonization (MRSA development)
Development-stage intranasal spray formulation intended to decolonize MRSA from the nasal cavity prior to surgery.
Oligonucleotide-based nanoparticulate antibacterial platform
A platform technology combining bioinformatics-designed oligonucleotide transcription factor decoys with nanoparticle carriers to inhibit essential bacterial genes and treat infections across designed spectra.
Lead narrow‑spectrum antibacterial candidate (CRE focus)
A lead compound in lead optimisation targeting Carbapenem-resistant Enterobacteriaceae (CRE), intended for development toward first-in-human studies.
Intranasal formulation for decolonization (MRSA development)
Development-stage intranasal spray formulation intended to decolonize MRSA from the nasal cavity prior to surgery.
Services
Collaborative research and development engagements with academic institutions, research institutes and clinical partners to adapt nanoparticulate oligonucleotide therapeutics for clinical indications.
Collaborative research and development engagements with academic institutions, research institutes and clinical partners to adapt nanoparticulate oligonucleotide therapeutics for clinical indications.
Expertise Areas
- Antibacterial drug discovery
- Nanoparticle drug delivery
- Oligonucleotide therapeutics
- Preclinical development and efficacy testing
Key Technologies
- Oligonucleotide transcription factor decoys
- Nanoparticle carrier systems
- Bioinformatics-driven therapeutic design
- Oral, intravenous, topical and intranasal formulations